[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"covid-19-pneumonia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:covid-19-pneumonia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,52,81,111,137,169,198,228,253],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100562348","cardiovascular-disease-progression-in-survivors-of-community-acquired-pneumonia-and-lung-infection-by-covid-19-100562348",false,"NCT06601998","Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.","A Non-interventional, Prospective, Cross-sectional Study of Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Sars-Cov-2","HOMI-LUNG CAP","Inclusion Criteria:\n\nGroup A (healthy controls)\n\n1. Adults (18 years or more) of both genders (Female\u002FMale: 50\u002F50 ratio)\n2. No history of severe pneumonia (sCAP, COVID-19 or HAP)\n3. Presence of no or one of the following comorbidities: obesity (defined as body mass index over 35 kg\u002Fm2), type 2 diabetes mellitus, hypercholesterolemia, essential arterial hypertension, or familial history of CVD.\n\nGroup B (CVRD controls)\n\n1. Adults (18 years or more) of both genders (Female\u002FMale ratio: 50\u002F50)\n2. No history of severe pneumonia (sCAP, COVID-19 or HAP)\n3. At least two of the following comorbidities: obesity (defined as body mass index over 35 kg\u002Fm2), type 2 diabetes mellitus, hypercholesterolemia, essential arterial hypertension, or familial history of CVD\n\nGroup C (COVID-19 survivors)\n\n1. Adults (18 years or more) of both genders (Female\u002FMale ratio: 50\u002F50)\n2. Survivors from severe COVID-19 pneumonia at hospital discharge; all patients had consolidation in chest X-ray or chest computed tomography during acute infection and were treated for pneumonia\n3. SoC treatment for acute COVID-19 with dexamethasone\n\nGroup D (sCAP survivors)\n\n1. Adults (18 years or more) of both genders\n2. Survivors from sCAP pneumonia; these patients may be either hospitalized in the ward with pO2FiO2 ratio less than 300 or require admission and hospitalization in the Intensive Care Unit.\n3. SoC treatment for sCAP with antibiotics\n\nExclusion Criteria:\n\nGroup A (healthy controls)\n\n1. Presence of two or more comorbidities\n2. Any other co-existing disorder generating CVRD symptoms\n3. Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians\n4. Pregnancy or lactation\n\nGroup B (CVRD controls)\n\n1. Any other co-existing disorder generating CVRD symptoms\n2. Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians\n3. Pregnancy or lactation\n\nGroup C (COVID-19 survivors)\n\n1. Medical history of severe congestive heart failure (Stage III-IV)\n2. Medical history of stage III or IV dyspnoea according to the New York Heart Association classification before the acute COVID-19\n3. Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians\n4. Pregnancy or lactation\n\nGroup D (sCAP survivors)\n\n1. Medical history of severe congestive heart failure (Stage III-IV)\n2. Medical history of stage III or IV dyspnoea according to the New York Heart Association classification before the sCAP\n3. Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians\n4. Pregnancy or lactation",true,"ALL","18 Years",{"count":21,"type":22},650,"ESTIMATED","OBSERVATIONAL","Pneumonia, which can be acquired in the community (including influenza and COVID-19), is a leading cause of mortality. The risk of severe cardiovascular diseases events (stroke, myocardial infarction, pulmonary embolism) increases after infections, but causal mechanisms are not understood yet. There is an essential need for improved understanding of the relationship between pneumonia and cardiovascular diseases and early identification of patients at risk of cardiovascular events to develop tailored therapies.\n\nThe overall concept underpinning \"Homi-lung\" is to investigate the time course of host-microbiome interactions during \\& after pneumonia to i) understand the causal relationship between trained immunity, microbiome dysbiosis and cardiovascular and respiratory diseases (CVRD) progressions, ii) define endotypes of pneumonia associated with response to treatment \\& CVRD history; iii) develop biomarkers to predict the individual response to the treatment \\& CVRD progression, and iv) preclinically validate therapeutical approaches for CVRD during \\& after pneumonia.",[26,27,28],"Pneumonia, Community-Acquired","COVID-19 Pneumonia","Cardiovascular Diseases",[30,31,32,33,34,35,36,37,38],"Covid-19","SARS-CoV-2","Lung infection","Cardiovascular disease","Respiratory disease","Endotypes","Biomarkers","Cardiorespiratory","Economic cost","RECRUITING","2026-06-09",{"date":42,"type":43},"2026-06-10","ACTUAL",{"date":45,"type":43},"2024-11-08",{"date":47,"type":22},"2028-06-08",{"name":49,"class":50},"Hellenic Institute for the Study of Sepsis","OTHER",18,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":61,"conditions":62,"keywords":69,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100451918","cardiac-magnetic-resonance-tissue-characterization-in-covid-19-survivors-100451918","NCT05164744","Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors","Cardiac Magnetic Resonance for Tissue Characterization-Based Risk Stratification of Cardiopulmonary Symptoms, Effort Tolerance, and Prognosis Among COVID-19 Survivors","Inclusion Criteria:\n\n* Emergency room presentation and\u002For hospitalization with COVID-19 infection defined in accordance with established criteria as follows: SAR-CoV2 RT-PCR+ (severe acute respiratory syndrome coronavirus 2 reverse transcription polymerase chain reaction) and at least one of the following symptoms: dyspnea, cough, dysphagia, rhinorrhea, diarrhea, nausea\u002Fvomiting, myalgias, fever, syncope\u002Fpresyncope.\n\nExclusion criteria:\n\n* Contraindication to CMR (i.e. non-compatible pacemaker\u002Fdefibrillator) or gadolinium (known hypersensitivity, eGFR (estimated globular filtration rate) \\\u003C30 ml\u002Fmin\u002F1.73m2).\n* Inability to provide informed consent (e.g. cognitive impairment).\n* Unrelated condition (e.g. neoplasm) with life expectancy \\\u003C12 months prohibiting follow-up.\n* Patients with contraindications to gadolinium (known or suspected hypersensitivity, glomerular filtration rate \\\u003C 30 ml\u002Fmin\u002F1.73m2) will undergo non-contrast MRI but will not be excluded from this study.\n* Patients with known or suspected pregnancy based on Weill Cornell Radiology intake surveys (reviewed by a clinical RN (registered nurse), as well as research personnel) will be excluded from the protocol.",{"count":60,"type":22},510,"The purpose of this study is to test if visualizing the heart with cardiac MRI\u002Fecho will be important in the understanding cardiac function and prediction of cardiopulmonary symptoms, physical effort tolerance, and outcomes in COVID-19 survivors. If successful, the research will allow us to identify the causes of lasting cardiopulmonary symptoms and begin developing cardiac and lung directed therapies accordingly.",[27,63,64,65,66,67,68],"COVID-19","COVID-19 Respiratory Infection","COVID-19 Acute Respiratory Distress Syndrome","COVID-19 Lower Respiratory Infection","COVID-19 Acute Bronchitis","Coronavirus Disease 2019",[70],"coronavirus disease 2019,","2026-01-20",{"date":73,"type":43},"2026-01-22",{"date":75,"type":43},"2021-07-01",{"date":77,"type":22},"2026-07-30",{"name":79,"class":50},"Weill Medical College of Cornell University",3,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":63,"eligibilityCriteria":87,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":110},"100547003","passive-detection--sars-cov-2-covid-19-am-breathalyzer-protect-kiosk-for-operational-medicine-100547003","NCT06402318","Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine","A Prospective, Non-interventional, Observational Clinical Validation Study to Analytically Validate the A&M Breathalyzer PROTECT Kiosk Breath Capture System.","Inclusion Criteria:\n\n* Asymptomatic and symptomatic individuals 18 years and older\n* Receiving standard COVID-19, Flu and\u002For RSV screening and testing at BAMC\n* Do not have to be diagnosed with SARS-CoV-19 (COVID-19) but only be screened\n* Ability to understand consent\n\nExclusion Criteria:\n\n* Any individual under age of 18\n* Anyone unable to comply (or be assisted) with study procedures\n* Anyone not able to provide temperature thermal scan, and\u002For perform exhaled breath for approximately 8 seconds","89 Years",{"count":90,"type":22},100,"The primary objective of this effort will be to optimize and operationalize innovative passive surveillance systems and in parallel, the effort will identify, evaluate, and transition groundbreaking new technologies in diagnostics for operationalization.\n\nTo meet the objective and execute the deliverables for this program of effort, the A\\&M Breathalyzer PROTECT Kiosk will be tested, modified and validated at Brooke Army Medical Center (BAMC). The collaborative efforts between the PI, Dr. Michael Morris at BAMC and Co-Investigator Dr. Tony Yuan at USU- Center for Biotechnology (4D Bio3) will assess the passive detection technology and provide a capability survey of use-case scenarios for different operational settings.\n\nGoals:\n\n1. Optimization and operationalize the A\\&M Breathalyzer PROTECT Kiosk, portable mass spectrometer (MS) Detector for Deployment in Military Operational Medicine Environments. The Breathalyzer will be deployed to BAMC to test its detection capabilities of COVID-19 among symptomatic and asymptomatic COVID-19 carrier vs. those not infected compared to gold standard RT-PCR.\n2. Evaluate the passive sensing, breath capture system, built within the A\\&M Breathalyzer PROTECT Kiosk. The conversion of the active breath capture system, currently requires a straw that the subject breaths into, where then a series of sensors built in the Breathalyzer would automatically sample the exhaled breath within proximity for recent COVID-19 exposure. This task would conclude with a set of sensors and sensor inputs that would be analyzed by the Atomic AI platform built in the device. Field testing at BAMC is planned to determine the level of detection and discrimination for sensor combinations to SARS-CoV2 components and biomarkers detected. This testing would update the Atomic AI algorithm, within the device, to understand the accuracy of positive detection and the resulting sensitivities.",[63,93,27,64,65],"SARS CoV 2 Virus",[95,96,97,98,99,100],"Breathalyzer","COVID-19 detection","Diagnostic Product","Pulmonary","PROTECT Kiosk","Passive Detection","2025-12-03",{"date":103,"type":43},"2025-12-10",{"date":105,"type":43},"2023-12-27",{"date":107,"type":22},"2026-03-30",{"name":109,"class":50},"The Geneva Foundation",1,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":18,"minAge":118,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":121,"phases":122,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":110},"100428390","study-of-hmb-enriched-amino-acid-supplementation-in-patients-with-alcoholic-liver-disease-and-covid-19-100428390","NCT04858412","Study of HMB-enriched Amino Acid Supplementation in Patients With Alcoholic Liver Disease and COVID-19","Evaluate the Molecular Mechanisms of HMB-enriched Amino Acid Supplement to Reverse Muscle Loss in Patients With Alcoholic Liver Disease and COVID-19","Inclusion Criteria:\n\nA. Cases: Patients with ALD and COVID-19 pneumonia:\n\n1. Clinical, imaging, laboratory, and\u002For histological diagnosis of alcoholic cirrhosis and\u002For alcoholic hepatitis\n2. Child Pugh score 5-8, serum creatinine \\\u003C3, Model for End Stage Liver Disease score (MELD) \\\u003C25\n3. Diagnosis of COVID-19 pneumonia as defined by the WHO criteria: confirmed SARS-CoV-2 infection by PCR, evidence of bilateral pulmonary infiltrates on chest radiograph (CXR) or computed tomography (CT) and SpO2 \\\u003C93% or on oxygen supplement\n4. Age of 21 years or older\n\nB. Controls: Patients without alcoholic liver disease (Non-ALD) and COVID-19 pneumonia:\n\n1. Diagnosis of COVID-19 pneumonia as defined by the WHO criteria: confirmed SARS-CoV-2 infection by PCR, evidence of bilateral pulmonary infiltrates on chest radiograph (CXR) or computed tomography (CT) and SpO2 \\\u003C93% or on oxygen supplement\n2. Age of 21 years or older\n\nExclusion Criteria: (Both Cases and Controls)\n\n1. Patients requiring active ventilator support\n2. Anticoagulant\u002Fantiplatelet therapy (for those in the biopsy arm, see Randomization schema. If clinically feasible, patients will be asked to hold their anticoagulants for the muscle biopsy after physician review),\n3. Recent gastrointestinal bleeding (\\\u003C3 months)\n4. Advanced organ diseases: congestive heart failure (NYHA class 3 and 4), chronic obstructive pulmonary diseases (COPD) (GOLD stage 3 and 4), chronic kidney disease (Cr\\>3), metastatic malignancy\n5. Medications that alter muscle protein metabolism except systemic corticosteroids\n6. Pregnancy\n7. Unwillingness\u002F Inability to sign informed consent","21 Years",{"count":120,"type":22},48,"INTERVENTIONAL",[123],"NA","Patients with COVID-19 and comorbidities including alcohol associated liver disease (ALD) are at risk for severe illness and abrupt or sudden clinical deterioration with ventilatory failure. â-hydroxy â-methyl butyrate (HMB), a non-nitrogenous leucine metabolite with anabolic properties, increases muscle mass and contractile function and enhances immune function. We aim to study the natural course of COVID-19 in patients with ALD and test whether HMB can affect ventilatory deterioration and improve short and long-term morbidity, mortality, and recovery from critical illness in symptomatic COVID-19 patients with ALD.",[126,127],"Alcoholic Liver Disease","COVID 19 Pneumonia","2025-11-24",{"date":130,"type":43},"2025-11-25",{"date":132,"type":43},"2021-04-01",{"date":134,"type":22},"2026-12-31",{"name":136,"class":50},"The Cleveland Clinic",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":146,"conditions":147,"keywords":150,"overallStatus":159,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":110},"100457594","imbalances-of-regional-pulmonary-ventilation-in-patients-with-post-acute-covid-19-100457594","NCT05238623","Imbalances of Regional Pulmonary Ventilation in Patients With Post-acute-COVID-19","Imbalances of Regional Pulmonary Ventilation in Patients With Post-acute-COVID-19 Symptoms","Inclusion Criteria:\n\n* all patients undergoing a Chest CT due to suspected post-acute-Covid-19-syndrome\n* \\>18 years\n* informed consent.\n\nExclusion Criteria:\n\n* trauma patients and patients with unstable spinal injuries or fractures\n* patients with an BMI over 50\n* patients with uncontrolled body movements\n* Patients with a pacemaker",{"count":145,"type":22},50,"Investigation of the correlation of CT-morphological changes of the lung compared to regional ventilation distribution on electrical impedance tomography in patients with post-acute-Covid-19 symptoms.",[27,148,149],"Post-acute COVID-19 Syndrome","Electric Impedance",[149,151,152,153,154,155,156,157,158],"CT","Tomography","regional ventilation","post-acute-COVID-19 syndrome","post-COVID-19","EIT","electroimpedance tomography","long-COVID","NOT_YET_RECRUITING","2025-09-22",{"date":162,"type":43},"2025-09-25",{"date":164,"type":22},"2025-10-01",{"date":166,"type":22},"2027-03-31",{"name":168,"class":50},"Jan-Christoph Lewejohann",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":17,"sex":176,"minAge":19,"maxAge":4,"enrollmentInfo":177,"targetDuration":179,"studyType":23,"phases":4,"briefSummary":180,"conditions":181,"keywords":183,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":197},"100587379","corona-virus-disease-2019-cohort-study-100587379","NCT06927622","Corona Virus Disease 2019 Cohort Study","Study on the Influence of Corona Virus Disease 2019 on Obstetric Outcome and Offspring Development","Inclusion Criteria:\n\n* Conduct regular prenatal examinations in the hospital and establish a pregnancy and childbirth health manual, planning for pregnant women who are hospitalized for delivery;\n* Conduct regular physical examinations in the hospital and establish a children's health manual for infants.\n* Age ≥ 18 years old\n\nExclusion Criteria:\n\n* Concomitant tumor related diseases;\n* Individuals with severe mental disorders.","FEMALE",{"count":178,"type":22},1000,"1 Year","The goal of this observational study is to learn about the influence of Corona Virus Disease 2019 on obstetric outcome and offspring development.",[27,182,63],"COVID-19 Pandemic",[184,185,186,187],"pregnant woman","birth cohort","infant","nervous system development","2025-04-14",{"date":190,"type":43},"2025-04-15",{"date":192,"type":43},"2023-04-01",{"date":194,"type":22},"2026-06-01",{"name":196,"class":50},"Shandong University",5,{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":206,"enrollmentInfo":207,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":209,"conditions":210,"keywords":215,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":110},"100453219","retrospective-analysis-of-chest-x-ray-severity-scoring-system-of-covid-19-pneumonia-100453219","NCT05181696","Retrospective Analysis of Chest X-ray Severity Scoring System of COVID-19 Pneumonia","Radiographic Severity Scoring System and Clinical and Laboratory Evolution of COVID-19 Pneumonia","RANCH-COVID","Inclusion Criteria:\n\n* Pneumonia caused by SARS-CoV-2 virus\n* Admission to the ICU COVID-19 unit\n\nExclusion Criteria:\n\n\\- Patients with lung tumors or history of lung resection","90 Years",{"count":208,"type":22},200,"The research will be retrospective, and will include all patients who were admitted during 2020 and 2021 in the COVID-19 ICU of University Hospital Center Osijek due to pneumonia caused by the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The association of chest x-ray infiltrate evolution with changes in laboratory inflammatory parameters and respiratory function parameters will be examined.",[27,211,212,213,214],"Sepsis","SARS-CoV-2 Acute Respiratory Disease","Pneumonia","Multiorgan Failure",[63,216,211,214,217,218],"Acute respiratory distress syndrome (ARDS)","Chest X-ray","Inflammation","2024-09-04",{"date":221,"type":43},"2024-09-19",{"date":223,"type":43},"2020-01-01",{"date":225,"type":22},"2025-05",{"name":227,"class":50},"Osijek University Hospital",{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":237,"conditions":238,"keywords":240,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":251,"locationsCount":110},"100554631","ai-based-system-for-assessing-suspected-viral-pneumonia-related-lung-changes-100554631","NCT06501599","AI-based System for Assessing Suspected Viral Pneumonia Related Lung Changes","Artificial Intelligence Based System for Assessing Suspected Viral Pneumonia Related Lung Changes According to Visual Pulmonary Lesion Grading System (CT 0-4): Retrospective Study","Inclusion Criteria:\n\n1. General\n\n   1. Patients over 18 years old;\n   2. Patients who underwent CT without contrast enhancement;\n   3. Patients who underwent a CT scan according to a standardized scanning protocol: 120 kilovolts, slice thickness max. 2 mm, rigid \"lung\" filter (kernel) reconstruction;\n   4. Patients whose studies should be of acceptable quality, performed with breath-holding, without technical artifacts, and respiratory and motor artifacts;\n   5. Patients whose studies must contain DICOM tags responsible for the orientation and position of the patient in the images during the study, as well as DICOM tags responsible for the size of the scans and image parameters;\n   6. Patients in whom the localization of changes is predominantly bilateral, in the basal and subpleural parts of the lungs, may be located peribronchial;\n2. For group Normal\n\n   a. Patients who do not contain COVID-19-related CT patterns;\n3. For groups Mild, Moderate, Severe, and Critical\n\n   1. Patients who contain COVID-19-related CT pattern: ground glass opacities (mild, moderate, and higher intensity);\n   2. Patients who contain COVID-19-related CT pattern: pulmonary consolidation;\n   3. Patients who contain COVID-19-related CT pattern: cobblestone infiltration of the lung parenchyma;\n   4. Patients who contain COVID-19-related CT pattern: hydrothorax;\n   5. Patients who contain a combination of one or more patterns.\n\nExclusion Criteria:\n\n* Patients whose studies contain images with unreported CT patterns;\n* Patients whose examinations do not conform to DICOM format;\n* Patients whose examinations do not contain imaging of the lung region\n* Patients whose examinations contain technical artifacts caused by malfunctions or features of CT scanners;\n* Patients whose examinations contain improper patient positioning;\n* Patients whose examinations contain studies with deleted DICOM tags responsible for scan size and image parameters;\n* Patients whose examinations contain metal artifacts on the patient's body and clothing;\n* Patients whose examinations contain the presence of other pathologic changes of lungs in patients - neoplastic, tuberculosis process, bacterial pneumonia, etc.;\n* Patients under 18 years old.",{"count":236,"type":22},563,"The AI-based system designed to process chest computed tomography (CT) aims to 1) detect the presence of pathologic patterns associated with interstitial changes in pneumonia; 2) highlight areas on the images with the probable presence of pathologies; 3) provide the physician with the results of image processing, including quantitative indicators of suspected viral pneumonia related lung changes according to visual pulmonary lesion grading system (CT0-4).\n\nThe retrospective study aims to demonstrate the clinical validation of the AI-based system. Clinical validation measures (sensitivity, specificity, accuracy, and area under the ROC curve) will be determined to provide evidence about the clinical efficacy of the AI-based system.\n\nThe hypothesis is that the measures of clinical validation of the AI-based system differ by no more than 8% from those declared by the manufacturer.",[239,27],"Pneumonia, Viral",[241,242,243,244],"Artificial Intelligence","Machine Learning","Computed tomography","Chest CT","2024-07-18",{"date":247,"type":43},"2024-07-22",{"date":249,"type":43},"2024-06-03",{"date":101,"type":22},{"name":252,"class":50},"Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department",{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":19,"enrollmentInfo":259,"targetDuration":179,"studyType":23,"phases":4,"briefSummary":261,"conditions":262,"keywords":265,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":110},"100484013","clinical-characteristics-and-long-term-impact-on-pediatric-covid-19-in-taiwan-100484013","NCT05582512","Clinical Characteristics and Long Term Impact on Pediatric COVID-19 in Taiwan","Inclusion Criteria:\n\n* COVID-19 positive cases\n\nExclusion Criteria:\n\n1. You have metal substances that cannot be removed or implanted, such as: braces, metal nails, artificial electronic ears, heartbeat pacemakers, etc. Because of the inability to perform brain MRI, it is not suitable to participate in this trial.\n2. Have major physical diseases.\n3. Sensory impairment, such as deafness.\n4. Movement disorders, such as cerebral palsy.\n5. Uncontrolled and stable epilepsy.\n6. Pregnant women are not suitable to participate in this test. (If you are pregnant or not sure if you are pregnant, please let the researcher know in advance so that a pregnancy test can be performed).\n7. Those who have suffered from hypoxia due to encephalitis or other reasons not caused by enterovirus infection are not suitable to participate in this test.",{"count":260,"type":22},3000,"This project will study severe COVID-19 related factors, host genes, biomarkers, and prognosis of severe encephalitis in children, and conduct:\n\n1. Retrospective clinical analysis of children with COVID-19, to analyze the clinical manifestations of children with new crown infection, and to find the relevant factors of severe disease.\n2. Prospective acceptance in the acute phase: mainly to understand the correlation between the interaction of host factors, viruses and microorganisms and the severity.\n3. Children's long COVID-19 Tracking Team An integrated outpatient clinic for \"Long COVID-19 Syndrome in Children\" will be established to conduct systematic tracking of body, lung function, nerves and psychology. Children with neurological complications or other confirmed diagnoses will undergo physical, neurological, pulmonary function and brain MRI and neurophysiological examinations, sleep examinations, and conduct psychiatric clinical diagnostic interviews to establish a psychiatric diagnosis. Status and family social function, the intelligence development status was examined by intelligence test, and cognitive function was measured by neuropsychological test. Understand the microbial phase, immune function and incidence of allergic diseases after long-term new coronavirus infection.\n4. Seroepidemiological Study Group Exploring the seroepidemiology of different groups of health care workers and non-health care workers will allow us to better understand the magnitude of natural infection among children and age groups in the community and the infection profile of health care workers during this period.\n\nThis trial includes multiple groups of prospective cases to explore the impact of the new coronavirus on children and the mechanism of severe illness, and integrates various specialties and branches of the Children's Hospital to conduct a summary trial, which is expected to understand children's new crown and community epidemiology, children infected with new crown Clinical manifestations of the virus, risk factors and effects on various systems, combined with host microbiome, immune function analysis and whole-exome sequencing, to improve the detection of new coronavirus (including long-term new coronary syndrome and pediatric multisystem inflammatory syndrome). Mechanisms of host factors and interactions with microbes to improve outcomes and severe incidence in children.",[263,27,264],"Long Covid19","Multisystem Inflammatory Syndrome in Children",[63,266,267],"long COVID","MIS-C","2023-11-15",{"date":270,"type":43},"2023-11-18",{"date":272,"type":43},"2022-07-01",{"date":274,"type":22},"2027-12",{"name":276,"class":50},"National Taiwan University Hospital"]